Insider Trading Alert - BancorpSouth And 2 Others Traded By Insiders

Wednesday, July 5, 2013, 60 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $43.14 to $23,490,709.49.

Highlighted Stocks Traded by Insiders:

BancorpSouth (BXS) - FREE Research Report

Clark Grace who is Director at BANCORPSOUTH bought 303 shares at $18.17 per share for a total value of $5,499.99 on July 1, 2013. Following this transaction, the Director owned 6,331 shares meaning that the stake was boosted by 5.02% with the 303 share acquisition.

Franklin Hassell Henry who is Director at BANCORPSOUTH bought 1.3 million shares at $9.09 per share for a total value of $10,124.99 on July 1, 2013. Following this transaction, the Director owned 1.3 million shares meaning that the stake was boosted by 4533052363.04% with the 1.3 million share acquisition.

Holliman Wilbert Glenn Jr who is Director at BANCORPSOUTH bought 142,036 shares at $9.09 per share for a total value of $11,249.99 on July 1, 2013. Following this transaction, the Director owned 709,580 shares meaning that the stake was boosted by 25.03% with the 142,036 share acquisition.

Hood Warren A Jr who is Director at BANCORPSOUTH bought 647 shares at $18.17 per share for a total value of $11,749.98 on July 1, 2013. Following this transaction, the Director owned 12,342 shares meaning that the stake was boosted by 5.53% with the 647 share acquisition.

Jackson Keith J who is Director at BANCORPSOUTH bought 605 shares at $18.17 per share for a total value of $10,999.98 on July 1, 2013. Following this transaction, the Director owned 13,689 shares meaning that the stake was boosted by 4.63% with the 605 share acquisition.

Kirk Larry G who is Director at BANCORPSOUTH bought 433 shares at $18.17 per share for a total value of $7,874.97 on July 1, 2013. Following this transaction, the Director owned 36,814 shares meaning that the stake was boosted by 1.19% with the 433 share acquisition.

Lashlee Turner Oscar who is Director at BANCORPSOUTH bought 495 shares at $18.17 per share for a total value of $8,999.99 on July 1, 2013. Following this transaction, the Director owned 87,667 shares meaning that the stake was boosted by 0.57% with the 495 share acquisition.

Mitchell Guy William Iii who is Director at BANCORPSOUTH bought 3,415 shares at $9.09 per share for a total value of $5,874.99 on July 1, 2013. Following this transaction, the Director owned 48,216 shares meaning that the stake was boosted by 7.62% with the 3,415 share acquisition.

Nolan Robert Calvert who is Director at BANCORPSOUTH bought 361,045 shares at $1.40 per share for a total value of $7,624.99 on July 1, 2013. Following this transaction, the Director owned 508,711 shares meaning that the stake was boosted by 244.5% with the 361,045 share acquisition.

Partee William Calhoun Jr who is Director at BANCORPSOUTH bought 34,862 shares at $2.02 per share for a total value of $10,249.98 on July 1, 2013. Following this transaction, the Director owned 333,037 shares meaning that the stake was boosted by 11.69% with the 34,862 share acquisition.

Patterson Aubrey Burns Jr who is Director at BANCORPSOUTH bought 123,280 shares at $6.06 per share for a total value of $16,087.46 on July 1, 2013. Following this transaction, the Director owned 521,060 shares meaning that the stake was boosted by 30.99% with the 123,280 share acquisition.

Perry Alan Walter who is Director at BANCORPSOUTH bought 303 shares at $18.17 per share for a total value of $5,499.99 on July 1, 2013. Following this transaction, the Director owned 84,012 shares meaning that the stake was boosted by 0.36% with the 303 share acquisition.

The shares most recently traded at $18.84, up $0.54, or 2.95% since the insider transactions. Historical insider transactions for BancorpSouth go as follows:

  • 24-Week # shares sold: 8,984

The average volume for BancorpSouth has been 672,200 shares per day over the past 30 days. BancorpSouth has a market cap of $1.7 billion and is part of the financial sector and banking industry. Shares are up 25.86% year to date as of the close of trading on Wednesday.

BancorpSouth, Inc. operates as a financial holding company for BancorpSouth Bank that provides commercial banking and financial services to individuals and small-to-medium size businesses. The stock currently has a dividend yield of 0.22%. The company has a P/E ratio of 21.0. Currently there is 1 analyst that rates BancorpSouth a buy, 1 analyst rates it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BXS - FREE

TheStreet Quant Ratings rates BancorpSouth as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, reasonable valuation levels, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full BancorpSouth Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

DaVita HealthCare Partners (DVA) - FREE Research Report

Berkshire Hathaway Inc who is 10% Owner at DAVITA INC bought 639,200 shares at $114.65 per share for a total value of $73,369,509.15 on July 2, 2013. Following this transaction, the 10% Owner owned 108.1 million shares meaning that the stake was boosted by 0.59% with the 639,200 share acquisition.

Weschler, R. Ted who is Member of 10% owner group at DAVITA INC bought 1.8 million shares at $72.96 per share for a total value of $73,369,509.15 on July 2, 2013. Following this transaction, the Member of 10% owner group owned 109.2 million shares meaning that the stake was boosted by 1.68% with the 1.8 million share acquisition.

The shares most recently traded at $114.56, up $0.66, or 0.58% since the insider transactions. Historical insider transactions for DaVita HealthCare Partners go as follows:

  • 4-Week # shares sold: 3,500
  • 12-Week # shares sold: 16,893
  • 24-Week # shares sold: 16,893

The average volume for DaVita HealthCare Partners has been 822,300 shares per day over the past 30 days. DaVita HealthCare Partners has a market cap of $12.1 billion and is part of the health care sector and health services industry. Shares are up 3.14% year to date as of the close of trading on Wednesday.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. The company has a P/E ratio of 27.3. Currently there are 8 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DVA - FREE

TheStreet Quant Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full DaVita HealthCare Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Onyx Pharmaceuticals (ONXX) - FREE Research Report

Fust Matthew K who is EVP & Chief Financial Officer at ONYX PHARMA INC sold 1,551 shares at $132.80 per share for a total value of $205,972.80 on July 2, 2013. Following this transaction, the EVP & Chief Financial Officer owned 97,799 shares meaning that the stake was reduced by 1.56% with the 1,551 share sell-off.

The shares most recently traded at $136.03, up $2.51, or 1.88% since the insider transaction. Historical insider transactions for Onyx Pharmaceuticals go as follows:

  • 4-Week # shares sold: 9,000
  • 12-Week # shares sold: 14,529
  • 24-Week # shares sold: 20,979

The average volume for Onyx Pharmaceuticals has been 1.5 million shares per day over the past 30 days. Onyx Pharmaceuticals has a market cap of $9.9 billion and is part of the health care sector and drugs industry. Shares are up 79.5% year to date as of the close of trading on Wednesday.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Currently there are 11 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ONXX - FREE

TheStreet Quant Ratings rates Onyx Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full Onyx Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

To Win at Trade the U.S. Must Act and Behave Like China

To Win at Trade the U.S. Must Act and Behave Like China

Dow Rises Sharply as U.S.-China Trade Tensions Thaw

Dow Rises Sharply as U.S.-China Trade Tensions Thaw

Video: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Apple Shares Gain as U.S. and China Call Off Trade War, For Now

Apple Shares Gain as U.S. and China Call Off Trade War, For Now

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec